Parkinson's Disease Study Reveals Potential Diagnostic and Therapeutic Approach

Strategic Insights -

A new study published in Biomolecules, a peer-reviewed journal, suggests that serotonin 5HT [ [1A] ] receptors may be affected in Parkinson's disease, providing a potential target for diagnostic and therapeutic approaches. Using the selective 5HT [ [1A] ] receptor positron emission tomography (PET) imaging agent, [[superscript]18F]mefway, researchers at the University of California Irvine conducted autoradiographic studies on postmortem human brains of individuals with Alzheimer's disease, Parkinson's disease, and cognitively normal subjects. The study found that levels of [[superscript]18F]mefway binding were significantly increased in the brains of individuals with Alzheimer's disease (+30%) and Parkinson's disease (+11%) compared to cognitively normal brains.

Key Takeaways:

  • The study suggests that serotonin 5HT [ [1A] ] receptors may be a potential target for diagnostic and therapeutic approaches for Alzheimer's disease and Parkinson's disease.
  • The use of [[superscript]18F]mefway, a selective 5HT [ [1A] ] receptor PET imaging agent, allowed researchers to study the availability of these receptors in human postmortem brains.
  • The study found significant increased binding of [[superscript]18F]mefway in the brains of individuals with Alzheimer's disease and Parkinson's disease compared to cognitively normal brains.
  • The increased availability of 5HT [ [1A] ] receptors in Alzheimer's disease and Parkinson's disease brains may be a response to lower serotonin levels due to increased MAO-A activity or other neuroinflammatory changes.
  • The study's findings support the potential use of 5HT [ [1A] ] receptors as a diagnostic and therapeutic target for Alzheimer's disease and Parkinson's disease.

Statistics:

  • 30% increase in [[superscript]18F]mefway binding in Alzheimer's disease brains compared to cognitively normal brains.
  • 11% increase in [[superscript]18F]mefway binding in Parkinson's disease brains compared to cognitively normal brains.
  • 6 subjects in each group (cognitively normal, Alzheimer's disease, Parkinson's disease) were analyzed in the study.
  • [[superscript]18F]mefway was used as a selective 5HT [ [1A] ] receptor PET imaging agent in the study.

Sources:

  • [[superscript]18F]Mefway: Imaging Serotonin 5HT [ [1A] ] Receptors in Human Postmortem Alzheimer's and Parkinson's Disease Anterior Cingulate. Potential Applications to Human Positron Emission Tomography Studies. Biomolecules, 2025,15(4):592.
  • NewsRx. Studies from University of California Irvine in the Area of Parkinson's Disease Published ([[superscript]18F]Mefway: Imaging Serotonin 5HT [ [1A] ] Receptors in Human Postmortem Alzheimer's and Parkinson's Disease Anterior Cingulate. Potential ...). Health & Medicine Week. May 16, 2025; p 7057.